Open an account

Agios Pharmaceuticals

AGIO · NASDAQ

$36.64+$1.74 (+4.99%)TodayMarket closed ·
Prev close $34.90

About AGIO

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. The company is headquartered in Cambridge, Massachusetts and currently employs 539 full-time employees. The company went IPO on 2013-07-24. The firm is focused on developing and delivering transformative therapies for patients living with rare diseases. The company markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its portfolio, PYRUKYND (mitapivat), is an activator of both wild-type and mutant pyruvate kinase, or PK, enzymes for the potential treatment of hemolytic anemias. The company is also developing tebapivat, a novel PK activator, for the potential treatment of lower-risk myelodysplastic syndromes, or LR MDS, and hemolytic anemias; AG-181, its phenylalanine hydroxylase, or PAH, stabilizer for the potential treatment of phenylketonuria, or PKU; and AG-236, an siRNA in-licensed from Alnylam Pharmaceuticals, Inc., targeting the transmembrane serine protease 6, or TMPRSS6 gene for the potential treatment of polycythemia vera, or PV.

Employees
539
Headquarters
Cambridge, Massachusetts
Listed
Jul 24, 2013
Sector
Health Care
Industry
Biotechnology
Website
agios.com

AGIO key statistics

Market cap
2.19B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.20M
Volume
1.52M
Open price
$35.04
High today
$37.00
Low today
$35.02
52 Week high
$46.00
52 Week low
$22.24

Agios Pharmaceuticals (AGIO) at a glance

As of Oct 20, 2026, Agios Pharmaceuticals (AGIO) shares are priced at $36.64, giving the company a market cap of 2.19B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $35.02 and $37.00. The current price is 4.6% above the day's low and 1.0% below its high.

Volume so far is 1.52M shares, above the average of 1.20M shares a day.

Over the past year Agios Pharmaceuticals has ranged from $22.24 to $46.00, and now sits 61% of the way up that range.

Agios Pharmaceuticals met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported -$1.69 per share against an estimate of -$1.70.

The average analyst price target is $48.96, 33.6% above the current price, from 9 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

67%of 9 analyst ratings say Buy
  • Buy66.7%
  • Hold33.3%
  • Sell0.0%
Price target · 10 analystsAvg $48.96
Low
$32.32
Now
$36.64
High
$76.65

AGIO earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 9.1% on average.

  1. Q3 FY24: reported -$2.42 per share against an estimate of $1.13
  2. Q4 FY24: reported -$1.44 per share against an estimate of -$1.72
  3. Q1 FY25: reported -$1.55 per share against an estimate of -$1.82
  4. Q2 FY25: reported -$1.93 per share against an estimate of -$1.84
  5. Q3 FY25: reported -$1.78 per share against an estimate of -$1.94
  6. Q4 FY25: reported -$1.86 per share against an estimate of -$1.99
  7. Q1 FY26: reported -$1.69 per share against an estimate of -$1.84
  8. Q2 FY26: reported -$1.69 per share against an estimate of -$1.70

AGIO news

  • Press releasePRNewswire

    A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on Monday

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO

  • Press releaseGlobe Newswire

    Agios Reports Second Quarter 2026 Financial Results and Provides Business Update

  • Press releaseGlobe Newswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO

  • Vandana Singh

    Agios Reports Neutral Sickle Cell Data, Decides To Stop Development

  • Vandana Singh

    Why Is Agios Pharma Stock Soaring Tuesday?

  • Press releaseBusiness Wire

    Avanzanite Bioscience's Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia

Similar companies

Companies in the same industry as Agios Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.